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Abstract
Background: Serum uric acid levels is reported to be associated with a variety of cardiometabolic risk factors;
however, its direct association with metabolic syndrome (MetS) remains controversial. Thus, we examined the
association of serum uric acid concentrations with the MetS components.
Methods: MetS was defined according to the National Cholesterol Education Program (NCEP) criteria. This case–control
study comprised 101 non-smoking individuals (41 in the MetS group and 60 in the non-MetS group). Blood pressure,
fasting plasma glucose, insulin, HOMA-IR, lipid profiles, uric acid, and anthropometric measures were determined, and
body composition was assessed by using bioelectrical impedance analysis (BIA).
Results: After adjustment for confounding factors, serum uric acid was significantly higher in MetS group than non-MetS
group (5.70 ± 1.62 vs 4.97 ± 1.30 mg/dL, respectively, P = 0.001). After controlling for age, sex and body mass index in
partial correlation analysis, uric acid was positively correlated with triglycerides, and negatively with HDL-C. In multiple
logistic regression analysis, every 1 mg/dl elevation in the serum uric acid level increased the risk of MetS approximately
by 2-folds (OR: 2.11, 95 % CI: 1.30-3.41).
Conclusion: This study showed that those individuals with MetS have higher uric acid levels; the association of uric acid
and MetS components supports that it might be an additional components of MetS.
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Introduction
Metabolic syndrome (MetS) is defined by a cluster of
risk factors, including obesity, dyslipidemia, hyperten-
sion and insulin resistance [1]. When occurring together,
they increase the risk of developing cardiovascular dis-
ease (CVD) and diabetes [2]. Previous studies have
shown that the defined MetS risk factors cannot explain
all CVD events observed in these subjects. Therefore,
several other risk factors such as inflammatory markers,
microalbuminuria, hyperuricemia and disorders of
coagulation have been debated to be included in the
MetS definition [3–6]. The prevalence of MetS is
increasing worldwide including Asian countries [7], and
a high prevalence of MetS (30.1 %) has been reported in
Iran [8].
Serum uric acid is a final enzymatic product of purine
metabolism in humans, and it is suggested that hyperuri-
cemia is associated with MetS, and they may have com-
mon pathophysiology [9]. In addition to MetS, elevated
concentrations of uric acid are associated with a variety
of cardiovascular conditions [10]. However, the associ-
ation of uric acid and MetS remains controversial and
limited experience exists on this relationship. Given the
high prevalence of MetS in Iranian population, in the
present study we evaluated the association of serum uric
acid levels and MetS components in the present study.
Methods
This case–control study was conducted from February
to July 2011 on 105 individuals who were selected by
simple random sampling method among persons who
accompanied patients referred to the vaccination and
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dental clinics of a public hospital (Shariati Hospital) in
Tehran, Iran. The eligibility criteria consisted of being
aged 30–49 years, and having no history of cardiovascu-
lar disease, diabetes, cancer, stroke, kidney diseases, and
gout.
From selected individuals, 4 who had heart failure and
kidney disease were not included to the study, and the par-
ticipants consisted of 41 persons as the MetS group, and
60 as controls. MetS was defined according to the third re-
port of the National Cholesterol Education Program Adult
Treatment (NCEP) (Panel III) [11], i.e. having at least three
of the following components: high serum triglycerides
(TG) concentrations (≥150 mg/dl and/or use of lipid low-
ering medication); low serum HDL- cholesterol (HDL-C)
concentrations (<40 mg/dl in men and <50 mg/dl in
women); elevated blood pressure (BP) (≥130/85 mmHg
and/or use of anti-hypertensive medication); abnormal
glucose homeostasis (fasting plasma glucose(FPG) ≥
100 mg/dl and/or use of insulin or oral hypoglycemic
medication); and enlarged waist circumference (WC).
The cutoffs for enlarged WC were set at > 89 cm in
men and > 91 cm in women, based on guidelines for the
First Nationwide Study of the Prevalence of Metabolic
Syndrome in Iran [8]. The Ethics Committee of Endo-
crine and Metabolism Research Institute, Tehran
University of Medical Sciences approved the study
protocol, and informed written consent was obtained
from all participants.
Anthropometric and blood pressure measurement
Fat mass (FM, kg) and fat-free mass (FFM, kg) were es-
timated by means of bioelectrical impedance analysis
(BIA; BC- 418MA, Tanita Company, USA) through the
use of 8 polar electrodes. Body circumferences were
measured at the umbilicus (waist circumference) and
at the most prominent buttock level (hip circumfer-
ence). Weight was measured using digital scales (Seca,
Germany) while subjects were minimally clothed and
without shoes, recorded to the nearest 100 g. Height
was measured to the nearest 1 cm using a non-elastic
tape meter while subjects were in a barefoot standing
position, with their shoulders in a normal position.
Body mass index (BMI) was calculated as weight in ki-
lograms divided by the square of height in meters. The
WC was taken halfway between the iliac crest and the
lower rib margin, and hip circumference was measured
at the maximal level over the great femoral trochan-
ters, over light clothing, using an unstretched tape
meter without any pressure to the body surface, and
was recorded to the nearest 0.1 cm. BP was measured
twice in the right arm of subjects who had been resting
for at least 10 min in a seated position using a mercury
sphygmomanometer.
Laboratory measurements
A venous blood sample of participants was taken after a
12–14 h overnight fast, centrifuged within 2 h, and
refrigerated at −10 °C. Total cholesterol (TC) and TG
were determined enzymatically using Parsazmun kits
(Tehran,Iran). HDL-C was measured similarly after pre-
cipitation with magnesium phosphotungstate. LDL-
cholesterol was calculated using Friedewald’s formula.
FPG was measured using the glucose oxidase method,
and immunoreactive insulin (IRI) was measured by
radioimmunoassay. Homeostasis Model Assessment
(HOMA) was used for the assessment of insulin resist-
ance. The HOMA index was calculated as FPG (mg/dl) ×
IRI (μU/ml)/405 [12]. Insulin was measured by radio-
immunoassay. Uric acid level was determined on a stand-
ard auto analyzer with Uricase and reagent (Parsazmun
Co.,Tehran,Iran).
Statistical analysis
Results are expressed as mean ± standard deviation (SD).
Kolmogorov Smirnov test was used to examine the nor-
mality of variables of interest. Continuous variables were
compared by T-test. The relationship between uric acid
level and other variables including MetS components
were assessed by Pearson’s correlation coefficients. A lo-
gistic regression analysis was performed to examine the
relationship between serum uric acid and the diagnosis
of MetS. P-value less than 0.05 was considered signifi-
cant. All statistical analyses were carried out using the
statistical program SPSS (version 13, SPSS).
Results
The average age of study population was 38.5 ± 6.0 years.
The clinical and metabolic characteristics of the study
participants are summarized in Table 1. Subjects in the
MetS group had higher BMI, WC, lean body mass
(LBM), body fat mass (BFM), trunk fat mass, SBP, DBP,
FPG, insulin, HOMA index, TG, TC, LDL, and lower
HDL levels than the subjects in the non-MetS group. In
this study, mean serum uric acid was significantly higher
in MetS group than that in the non-MetS group (Fig. 1),
even after adjustment for age, sex and BMI (5.70 ± 1.62
and 4.97 ± 1.30, P = 0.001 in MetS and non-MetS group,
respectively).
Table 2 shows partial correlations between serum
uric acid and anthropometric and biochemical vari-
ables. Serum uric acid continued to have a significant
correlation after adjusting for age and sex (model 1),
except for SBP, FPG, TC and LDL-C. In this model,
there were significant correlation between uric acid
levels and insulin, HOMA-IR and body fat mass. After
more adjustment for BMI, uric acid had significant
correlation just with TGs (r = 0.322, P = 0.004) and
with HDL-C (r = − 0.324, P = 0.003).
Nejatinamini et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:70 Page 2 of 7
Table 3 shows the association of serum uric acid level
for the diagnosis of MetS in the logistic regression ana-
lysis. There were increases in ORs after adjustment for
age and gender. The result of regression model showed
that in model III (age, sex and BMI adjusted) for every
1 mg/dl elevation in the serum uric acid level the odds
ratio for developing metabolic syndrome increased ap-
proximately 2-fold (OR:2.11, 95 %CI: 1.30-3.41).
Spearman’s correlation coefficient analysis revealed
that the mean serum uric acid increased with increasing
number of MetS components (r = 0.335, P =0.001)
(Fig. 2). Because of few numbers of subjects with 4 and
Table 1 Characteristics of the participants with or without metabolic syndrome
Variables MetS group (n = 41) non-MetS group (n = 60) P-value
Age, years 40.66 ± 6.01 37 ± 5.57 0.002
Body mass index, kg/m2 28.74 ± 3.73 25.79 ± 3.70 <0.001
Waist circumference, cm 95.10 ± 15.16 88.65 ± 8.58 0.011
Fat free mass, kg 55.56 ± 12.14 51.28 ± 9.28 0.048
Fat mass, kg 24.92 ± 7.6 19.26 ± 6.55 <0.001
Trunk fat mass, kg 13.37 ± 3.94 10.49 ± 3.31 <0.001
Systolic blood pressure, mmHg 122.8 ± 13.3 112.6 ± 12.5 <0.001
Diastolic blood pressure, mmHg 85.7 ± 10.3 78.3 ± 11.29 0.001
Fasting glucose, mg/dl 104.9 ± 12.1 95.8 ± 6.9 <0.001
Fasting insulin, μU/ml 12.6 ± 5.67 8.9 ± 4.36 <0.001
HOMA-IR 3.28 ± 1.49 2.12 ± 1.08 <0.001
Triglyceride, mg/dl 200.1 ± 130.3 102.4 ± 57.4 <0.001
Total cholesterol, mg/dl 200.9 ± 43.9 180.5 ± 30.6 0.007
LDL-C, mg/dl 123.8 ± 31.4 109.1 ± 24.1 0.009
HDL-C, mg/dl 42.7 ± 7.2 53 ± 11.7 <0.001
Uric Acid, mg/dl 5.87 ± 1.52 4.85 ± 1.28 <0.001
Data was expressed as mean ± SD
Fig. 1 Difference in serum uric acid level in the presence of metabolic syndrome
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5 MetS components and equal mean of uric acid in both
groups we merged data of these participants.
Discussion
In this study, we evaluated the associations of serum
uric acid levels with MetS components in individuals
with or without MetS. Serum uric acid levels were
significantly higher in the MetS group compared to
healthy individuals after considering covariates like
gender, age and BMI. This finding is in line with some
other studies [13–15]. Although hyperuricemia is well
recognized as a risk factor for atherosclerotic diseases
such as myocardial infarction and stroke [16, 17], its
independent association with cardiometabolic risk fac-
tors remained controversial. However, Zhang et al.
showed that uric acid is an independent risk factor of
MetS, and its higher concentrations increased the risk
of MetS [18].
We found that higher serum uric acid levels, even
within the normal ranges, were associated with an
increased odds ratio of MetS, and remained significant
even after adjusting for confounding factors. It is specu-
lated from this study that serum uric acid is one of the
determinants of the Mets. With one unit increasing of
serum uric acid, the odds of developing MetS approxi-
mately doubled. Similar findings have shown that indi-
viduals with high uric acid levels have 1.6 times higher
odds of developing MetS [19, 20]. However, the pre-
cise biological mechanisms underlying the association
between serum uric acid and development of MetS
remain unclear, although reduction in endothelial
nitric oxide bioavailability by uric acid is likely to be
involved [20]. Nitric oxide seems to play an important
role in the development of insulin resistance, and its
deficiency is believed to reduce blood flow to insulin-
sensitive tissues,i.e. skeletal muscle, liver, adipose tis-
sue, leading to block the action of insulin [21]. Fur-
thermore, hyperinsulinemia reduces urinary uric acid
excretion by the effect of insulin on urinary tubules
leading to hyperuricemia [22].
In the present study, after controlling for sex, age and
BMI, serum uric acid had significant relationship with
hypertriglyceridemia and low HDL-C. These findings are
in line with results of some other studies [23–27].
Several past studies have shown that high level of plasma
TG are related to hyperuricemia [28–30]. There are
some explanations for such relation. A potential mechan-
ism is that TG synthesis accelerates the de novo synthesis
of ribose-5-phosphate to phosphoribosyl pyrophosphate
(PPRP) through the common metabolic pathway of
NADP-NADPH, and as a result, uric acid production
increases [31]. Some previous studies reported negative
correlation between HDL-C and serum uric acid [32, 33].
The mechanisms of this relation may be due to the as-
sociation between decreased HDL-C levels and insulin
resistance [34].
Table 2 Partial correlation between uric acid and other variables
Variables Model I Model II Model III
Pearson’s coefficients p-value Pearson’s coefficients p-value Pearson’s coefficients p-value
Body mass index, kg/m2 0.245 0.014 0.26 0.016 ———————— ———————
Waist circumference, cm 0.377 <0.001 0.24 0.027 0.078 0.492
Body fat mass, kg 0.028 0.785 0.27 0.014 0.089 0.432
Trunk fat mass, kg 0.281 0.007 0.24 0.025 0.077 0.499
Systolic blood pressure, mmHg 0.400 <0.001 0.14 0.198 0.055 0.628
Diastolic blood pressure, mmHg 0.416 <0.001 0.24 0.031 0.158 0.161
Fasting glucose, mmol/L 0.298 0.002 0.08 0.429 0.013 0.908
Insulin 0.095 0.344 0.22 0.048 0.123 0.279
HOMA 0.157 0.116 0.22 0.043 0.119 0.293
Triglyceride, (mg/dL) 0.455 <0.001 0.30 0.005 0.322 0.004
Total cholesterol, (mg/dL) 0.200 0.045 0.07 0.495 0.087 0.445
LDL-C,(mg/dL) 0.213 0.032 0.11 0.316 0.086 0.449
HDL-C, (mg/dL) −0.454 <0.001 −0.372 0.001 −0.324 0.003
Model I: Crude model; Model II: Adjusted for age, gender; Model III: Adjusted for age, gender & BMI
Table 3 Association between uric acid level (mg/dl) and
metabolic syndrome in logistic regression models
Serum uric acid OR (95 % CI) P
Model I 1.70(1.23-2.33) 0.001
Model II 2.38 (1.49-3.81) <0.001
Model III 2.11 (1.30-3.41) 0.002
Model I, Crude model; Model II, adjusted for age and sex; Model III, further
adjusted for BMI
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The present study showed that higher concentrations
of serum uric acid were significantly associated with
increased number of MetS components. This finding has
been reported in some other similar studies [35–37].
It has been suggested that hyperuricemia can be an
additional components of MetS. Some studies have ar-
gued that the hyperuricemia should be included as an
additional MetS component [38, 39]. The results of
other studies showed that serum uric acid level was as-
sociated with a higher risk of MetS across a broad age
range [40, 41]. At present, hyperuricemia has not been
included among NCEP criteria as a component of Mets.
Our data show that serum uric acid was significantly as-
sociated with the diagnosis of MetS in the population
studied, however, longitudinal studies are needed to as-
sess whether hyperuricemia is an additional component
of the MetS or not.
Our findings are, in general, concordant with results
from previous reports [42–47], but can be distinguished
from them in some aspects. In our participants, serum
uric acid levels ranged from 2.5 to 8.9 mg/dL, whereas
most previous studies have analyzed the relation
between frank hyperuricemia [48–50] with MetS. As-
sessment of body composition and its relation with uric
acid is another novel aspect of this study. Trunk fat mass
had a significant correlation with serum uric acid. This
significant relation was seen for both body fat mass and
trunk fat mass after controlling for age and gender.
These results showed that the body fat mass, especially
trunk fat mass, could be related to serum uric acid.
Some studies reported the relationship of body fat mass
and serum uric acid. Hikita et al. reported that there
were significant relations between serum uric acid and
both visceral fat and total fat mass; in particular, serum
uric acid was more closely related to visceral fat [37]. It
is considered that insulin resistance caused by accumula-
tion of visceral fat is the underlying mechanism.
The limitations of this study warrant consideration.
Firstly, this study is limited due to its cross-sectional na-
ture, since a causal association between uric acid and
MetS could not be derived. Secondly, the sample size in
this study was relatively small which could limit the
generalization of our findings. It is also possible that un-
measured confounding variables may exist.
Conclusion
Serum uric acid had independent association with MetS
components, and increased the risk of MetS by near two
folds. Our findings propose that uric acid can be consid-
ered as a component of MetS. Regarding high prevalence
of obesity and MetS as well as the potential link between
hyperuricemia and CVD, future studies should be con-
ducted to clarify the role of uric acid in the pathogenesis
of Mets and the clinical significance of the current
findings.
Fig. 2 Mean and standard deviation of serum uric acid levels according to the number of metabolic syndrome components
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